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Background: Obesity is a major risk factor for the development of type 2 diabetes mellitus. Surgery is one of the
most effective treatments for morbid obesity. In a prospective cohort study, we examined the effects of Laparoscopic
Gastric Plication (LGP) as a new restrictive technique on remission of type 2 diabetes mellitus.
Methods: During six years of study from June 2007 through December 2013, 62 patients who underwent bariatric
surgery were recruited for our study to determine the effects of weight loss. Sixty patients with diabetes mellitus type 2
were selected for a one year follow up period. The amount of weight loss, Fasting Blood Sugar (FBS), changes in the
lipid profile, HbA1c and blood pressure were assessed during this period. The primary outcomes were safety and the
percentage of patients experiencing diabetes remission.
Results: Sixty patients with the mean age of 39.7 ± 12.8 years, ranging from 18 to 62 years, were enrolled in the study
for an average 12 months of follow up. The maximal weight loss of 57 kg was achieved at average after six months.
FBS significantly decreased during this period, and after one year, remission of diabetes was achieved in 92 % of
patients. In five patients, diabetes was controlled with decrease in taking oral medications.
Conclusions: Laparoscopic Gastric Plication (LGP) resulted in significant and sustained weight loss with minimal physiologic
changes in gastrointestinal tract and ameliorated blood glucose control of type 2 diabetes in morbid obese patients.
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Obesity and diabetes have reached to epidemic ratios and
are responsible for major health and economic burdens.
Diabetes is a chronic disease with potentially fatal compli-
cations. Approximately 26 million Americans have dia-
betes, while an estimated seven million patients with
diabetes are even unaware of their condition. Early and in-
tensive treatment of type 2 diabetes improves health out-
comes and quality of life [1]. In this regard, weight control
may be regarded as the most important aspect of type 2
diabetes management which significantly reduces morbid-
ity and mortality [2]. In fact, recent evidence indicates that
improvement in the control of blood glucose is related to
the amount of weight loss [3]. Unfortunately, the currently* Correspondence: khajavim@tums.ac.ir
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creativecommons.org/publicdomain/zero/1.0/available lifestyle and pharmacological interventions are
provided to help for only little to moderate amounts of
weight loss. Nonetheless, patients with diabetes experience
greater difficulty in losing weight than those without dia-
betes [4].
Recently, many studies compared the efficacy of bar-
iatric surgery (laparoscopic Roux-en-Y gastric bypass or
laparoscopic sleeve gastrectomy) with medical treatment
among patients with uncontrolled type 2 diabetes [5, 6].
New research has found that bariatric surgery is effective
in abating the symptoms of type 2 diabetes in the short
term as well as causing remission of diabetes in the long
term [7]. In fact, observational evidence suggests that
bariatric surgery is associated with a 60 %–80 % diabetes
remission rate among morbid obese persons [8]. Note-
worthy, bariatric surgery can help in the management of
obesity and diabetes at the same time, however, consid-
ering the invasive nature of such procedures, bariatrics article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Preoperative patient characteristics
Characteristics Range Mean ± SD
Age(yr) 18–62 39.7 ± 12.8
Weight (kg) 95–156 125 ± 14.1
BMI(kg/m2) 31–55 42.4 ± 5.47
HbA1c (%) 8–12 9.8 ± 0.5
FBS(mg/dl)impending to diabetes 108–135 118.22 ± 6.43
FBS(mg/dl) overt diabetes 136–295 180.33 ± 36.12
Total cholesterol(mg/dl) 196–327 226.0 ± 42.4
Triglycerides (mg/dl) 187–307 227.61 ± 8.4
Mean blood pressure (mmHg) 85–111 105.9 ± 6.8
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control guidelines [9]. Among these procedures, Laparo-
scopic Gastric Plication (LGP) is a new, less invasive and re-
strictive technique that reduces the gastric volume by
plication of the greater curvature [10].
In this prospective cohort study, we sought to deter-
mine the effectiveness of LGP induced weight loss in
controlling type 2 diabetes.Materials and methods
This prospective cohort study was conducted on 60
morbid obese patients with recently diagnosed type 2
diabetes (<3 years) who were candidates for LGP surgery
This trial was done from June 2007 to December 2013
at Sina hospital by a specialist general surgeon, who had
fellowship in advanced laparoscopic surgery. The tech-
nique of LGP was performed according to the standard
method based on the last paper of the author for all pa-
tients [11]. The Institutional Review Board (IRB) of
Tehran University of Medical Sciences reviewed and ap-
proved the study protocol.
All patients underwent thorough preoperative evalu-
ations including history and physical examination, nu-
tritional status and psychiatric status evaluations, and
specialty consultations as indicated. Preoperative eval-
uations also included complete blood count, urinalysis,
serum chemistries, levels of fasting lipids including
total cholesterol and triglycerides, electrocardiogram
and abdominal sonogram. Patients with a Body Mass
Index (BMI) greater than 30 and documented type 2Table 2 Postoperative patient’s outcomes during one year
Characteristics 3 month 6 month
Mean weight loss(kg) 42 ± 14.21 57.21 ± 1
Mean FBS(mg/dl) 105.81 ± 12.5 98.76 ± 8
HbA1c(%) 8.1 ± 0.2 6.5 ± o.6
Total cholesterol(mg/dl) 190 ± 8.2 178 ± 5.2
Triglycerides (mg/dl) 187 ± 6.3 171 ± 6.3
Mean blood pressure (mmHg) 92.03 ± 1.1 85.02 ± 2diabetes within the previous three years who were able
to understand the study protocol were enrolled in the
study. Also, presence of symptoms related to the diabetes
complications such as renal impairment or diabetic retin-
opathy were considered as the exclusion criteria. The cut
off value for the diagnosis of diabetes was 120 mg/dl of
Fasting Blood Sugar (FBS) or higher, and hemoglobin A1C
(HbA1c) levels ≥ 7 %. Progress of study was reviewed by
the bariatric surgery team every four to six weeks
throughout the study. The primary endpoint was the
rate of remission of diabetes after one year, defined as
FBS < 100 mg/dl and HbA1c levels < 6.5 % without
pharmacologic treatment for at least one year.
Data were presented as mean ± standard deviation
(SD) for continuous variables. For statistical analysis,
SPSS software (SPSS for Windows 18.0; SPSS Inc.,
Chicago, IL, USA) was used. Changes from baseline in the
metabolic parameters were evaluated with Bonferroni-
corrected-repeated-measures ANOVA and P values <0.05
were considered significant.Results
Among the 62 patients who were candidates for LGP, 60
were eligible. The mean age of patients was 39.7 ± 12.8 years,
ranging from 18 to 62 years. Twenty two patients were male
(37 %) and 38 were female (63 %). Preoperative data of
patients are outlined in Table 1. We were in contact
with all the patients during the one year follow up.
Twenty five patients were impending to diabetes.
Among patients with overt diabetes, 28 patients did not
take any drug and the rest of them took oral diabetes
drugs and insulin. According to postoperative results
(Table 2), participants had an average maximal weight
loss of 42 kg after three months. This trend of weight
loss was decreased after nine months. FBS declined sig-
nificantly six months after surgery, which was correlated
with the trend of weight loss during this period. The
mean HbA1c for the entire cohort decreased progres-
sively during the study from 9.8 % to 6.5 %. Most of this
change occurred within the first six months. Remission
of diabetes was achieved in 92 % of patients. In patients
who experienced remission, diabetes medications were
discontinued 4–22 weeks after surgery. In five patients,9 month 12 month P value
6.62 61.12 ± 14.21 69.05 ± 13.21 0.001
.35 95.36 ± 7.24 91.25 ± 8.12 0.0001
6.1 ± o.4 5.6 ± o.4 0.002
168 ± 6.2 150 ± 2.1 0.001
140 ± 5.4 115 ± 6.5 0.001
.3 76.12 ± 2.1 75.5 ± 1.4 0.001
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betes medications. The changes in lipid profile and
hypertension were correlated with the trend of weight
loss after surgery. We did not find any correlation be-
tween remission of diabetes and age, gender or the class
of weight category according to BMI during the study
(P > 0.05).
Discussion
In this study, we showed that gastric plication promotes
remission of type 2 diabetes among morbid obese pa-
tients. Complete diabetes remission was achieved in
92 % of patients, with improvement of blood glucose
levels in the remaining 8 % of patients. The observed
improvement in the control of blood glucose was ac-
companied by substantial improvements in hypertension
and dyslipidemia.
Most people with type 2 diabetes experience problems
in losing weight. Although medications are useful in im-
proving blood sugar, their benefits are quite limited
among obese and particularly morbid obese patients.
Unfortunately losing weight is very difficult with going
on a diet, exercise and drug therapy for most patients.
Therefore, surgery is very effective for losing weight
among diabetic patients. In fact, weight loss decreases
insulin resistance and improves blood sugar levels. The
results of the trial done by Carlson et al. show that
bariatric surgery reduces the long-term incidence of
type 2 diabetes by 78 % in obese patients. Among pa-
tients with impaired fasting glucose, bariatric surgery
reduced the risk by 87 %, and diabetes type 2 did not
develop in 10 out of 13 obese patients who underwent
bariatric surgery [12]. In addition, there is substantial
evidence that bariatric surgery provides additional
quality-of-life improvements and reduces mortality in
patients with type 2 diabetes. It is noteworthy that
Improvement of insulin sensitivity by means of weight
loss may not be enough to induce the remission of
diabetes if there is advanced destruction of beta cells.
Also, the diabetes remission rate is inversely related to the
duration of diabetes at the time of bariatric surgery [13].
Several mechanisms have been proposed for the im-
provement of blood glucose control through weight
loss. There seems to be improved gastrointestinal hor-
mone level changes after surgery such as Glucagon-
like Peptide-1(GLP-1) [14]. After bariatric surgery,
rapid delivery of partially digested nutrients to the
distal bowel up-regulates the secretions of gut hor-
mones such as glucagon-like peptide-1 (GLP-1). The
result of the increased gut hormone secretion is an en-
hanced glucose-dependent insulin secretion as well as
a number of other changes that cause improved glu-
cose tolerance [15]. In a non-obese diabetic rat model,
surgical diversion of the proximal bowel caused rapidimprovement in diabetes without reduction of food in-
take or change in weight. Duodenal exclusion does not
play a significant role alone in postsurgical amelioration
of diabetes type 2 and restoration of gut hormone pro-
file in lean diabetic rodents [16]. In our study, greater
curvature of stomach was inverted to lumen of stomach
and there was no resection or change in the physiology of
gastrointestinal tract; however, weight loss and remission
of diabetes occurred in most patients. Nonetheless, many
aspects regarding the applications of surgical treatment of
type 2 diabetes are still questionable and unresolved.
This study has several limitations. First, the follow up
period was one year and it would be better to follow the
patients for a longer period. Additionally, identifying the
gut hormone levels before and after bariatric surgery
may be helpful.
Conclusion
Laparoscopic Gastric Plication (LGP) with minimal
physiologic changes in the gastrointestinal tract amelio-
rates overall blood glucose control of type 2 diabetes in
morbid obese patients.
Abbreviation
LGP: laparoscopic gastric plication 1; DM T2: diabetes mellitus type 2.
Competing interests
The authors declare that they have no competing interests.
Authors' contribution
MT designed and run the surgery, AT conducted the study, GB analyzed the
results, MRK drafted the article and RSM edited the draft. All authors read
and approved the final manuscript.
Acknowledgements
Authors would like to thank Sina Hospital Research Center for their valuable
technical help.
Author details
1Department of surgery, Laparoscopic Ward, Sina Hospital, Tehran University
of Medical Sciences, Tehran, Iran. 2Department of Anesthesiology, Tehran
University of Medical Sciences, Sina Hospital, Hassan Abad Square, Tehran
Zip code: 1136746911, Iran.
Received: 2 February 2015 Accepted: 7 July 2015
References
1. UK Prospective Diabetes Study Group. UK prospective diabetes study 16:
overview of 6 years' therapy of type II diabetes: a progressive disease.
Diabetes. 1995;44(11):1249–58.
2. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T.
Intentional weight loss and mortality among overweight individuals with
diabetes. Diabetes Care. 2000;23(10):1499–504.
3. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Serdula M, et al.
Long-term effectiveness of lifestyle and behavioral weight loss
interventions in adults with type 2 diabetes: a meta-analysis. Am J Med.
2004;117(10):762–74.
4. Khan MA, St Peter JV, Breen GA, Hartley GG, Vessey JT. Diabetes disease
stage predicts weight loss outcomes with long-term appetite suppressants.
Obes Res. 2000;8(1):43–8.
5. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G,
et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes
mellitus. Ann Surg. 2003;238(4):467–84. 84–85.
Talebpour et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:60 Page 4 of 46. Zhang C, Yuan Y, Qiu C, Zhang W, A Meta-analysis of 2-Year Effect After Surgery.
Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy
for Morbid Obesity and Diabetes Mellitus. Obes Surg. 2014;24(9):1528–35.
7. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al.
Bariatric surgery versus intensive medical therapy in obese patients with
diabetes. N Engl J Med. 2012;366:1567–76.
8. Dixon JB, Pories WJ, O’Brien PE, Schauer PR, Zimmet P. Surgery as an
effective early intervention for diabesity: why the reluctance? Diabetes Care.
2005;28(2):472–4.
9. American Diabetes Association. Standards of medical care in
diabetes—2007. Diabetes Care. 2007;30:(suppl 1) S4-S41, American Diabetes
Association. Standards of medical care in diabetes—2007. Diabetes Care.
2007;30 suppl 1:4-S41.
10. Talebpour M, Amoli BS. Laparoscopic total gastric vertical plication in
morbid obesity. J Laparoendosc Adv Surg Tech A. 2007;17:793–8.
11. Talebpour M, Motamedi SM, Talebpour A, Vahidi H. Twelve year experience
of laparoscopic gastric plication in morbid obesity: development of the
technique and patient outcomes. Ann Surg Innov Res. 2012;22:6–7.
12. Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al.
Bariatric surgery and prevention of type 2 diabetes in Swedish obese
subjects. N Engl J Med. 2012;367:695–704.
13. Hall TC, Pellen MG, Sedman PC, Jain PK. Preoperative factors predicting
remission of type 2 diabetes mellitus after Rouxen- Y gastric bypass surgery.
Obes Surg. 2010;20(9):1245–50.
14. Kindel TL, Yoder SM, Seeley RJ, D’Alessio DA, Tso P. Duodenaljejunal
exclusion improves glucose tolerance in the diabetic, Goto- Kakizaki rat by a
GLP-1 receptor-mediated mechanism. J Gastrointest Surg. 2009;13:1762–72.
15. Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action
and glucose tolerance in subjects with remission of type 2 diabetes after
gastric bypass surgery. Diabetes Care. 2013;36(7):2062–9.
16. Spector D, Shikora S. Neuro-modulation and bariatric surgery for type 2 diabetes
mellitus. Int J Clin Pract Suppl. 2010;166:53–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
